Titratable Control of blood pressure reduction with CLEVIPREX® (clevidipine)
CLEVIPREX—a dihydropyridine calcium channel blocker—can provide blood pressure (BP) reduction in the perioperative setting and in acute severe hypertension cases.
Non–weight-based dosing regimen that is independent of renal or hepatic function1
CLEVIPREX is a low-volume, non–weight-based dosing regimen for individualized, titratable administration.1
Calculate Dosing
Proven efficacy in clinical studies
- Over 90% of patients with perioperative hypertension achieved treatment success (≥15% BP reduction from baseline)2,3
- Low rate of overshoot in acute severe hypertension patients in the VELOCITY trial4
BP reduction within minutes
In perioperative patients, CLEVIPREX produces a 4%–5% reduction in systolic blood pressure (SBP) within 2–4 minutes of initiation. An approximately 1–2 mg/hr increase will generally produce an additional 2–4 mmHg decrease in systolic pressure.
Demonstrated safety profile
The safety profile of CLEVIPREX was evaluated in multiple clinical trials.1
Get information
Sign up to get information about CLEVIPREX or request communication from a Chiesi sales representative.
